New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 3, Pages 688
Publisher
MDPI AG
Online
2020-03-13
DOI
10.3390/cells9030688
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic therapies for intrahepatic cholangiocarcinoma
- (2020) Robin Kate Kelley et al. JOURNAL OF HEPATOLOGY
- Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism
- (2019) Germana Castelli et al. Cancers
- Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
- (2019) Maria Maddalena Simile et al. Medicina-Lithuania
- Signaling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance
- (2019) Laura Fouassier et al. LIVER INTERNATIONAL
- Second‐line chemotherapy in biliary tract cancer: Outcome and prognostic factors
- (2019) Nora Schweitzer et al. LIVER INTERNATIONAL
- Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
- (2019) Julien Edeline et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
- (2019) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
- (2019) Richard D. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of tumor shrinkage pattern by biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancers: Implication for neoadjuvant therapy (KHBO1401-1A study).
- (2019) Shogo Kobayashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma
- (2019) Minfeng Ye et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- Antitumor Activity of a Novel Fibroblast Growth Factor Receptor (FGFR) Inhibitor for Intrahepatic Cholangiocarcinoma
- (2019) Chiara Raggi et al. AMERICAN JOURNAL OF PATHOLOGY
- Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
- (2019) Awa Sarr et al. Scientific Reports
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
- (2019) G K Abou-Alfa et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Targeting cholangiocarcinoma
- (2018) Joachim C. Mertens et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
- (2018) T. Ebata et al. BRITISH JOURNAL OF SURGERY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
- (2018) Sarah P. Blagden et al. BRITISH JOURNAL OF CANCER
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
- (2017) Marie Bréchon et al. INVESTIGATIONAL NEW DRUGS
- Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
- (2017) Tomohiro Nishina et al. INVESTIGATIONAL NEW DRUGS
- Emerging molecular therapeutic targets for cholangiocarcinoma
- (2017) Sumera Rizvi et al. JOURNAL OF HEPATOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: A Multicenter Retrospective Study
- (2017) Talia Golan et al. ONCOLOGIST
- Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis
- (2017) Michele Ghidini et al. HPB
- Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
- (2017) Daniel Thomas et al. Cancer Discovery
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
- (2017) Nader N. Massarweh et al. Cancer Control
- Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers
- (2017) Rafael Santana-Davila et al. JAMA Oncology
- Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare
- (2017) Jessica L. Petrick et al. PLoS One
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
- (2016) Faiz Gani et al. ANNALS OF SURGICAL ONCOLOGY
- HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
- (2016) Salvatore Galdy et al. CANCER AND METASTASIS REVIEWS
- The case for immune-based approaches in biliary tract carcinoma
- (2016) Austin G. Duffy et al. HEPATOLOGY
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dauerhafte Remission unter dualer HER2-Blockade mit Trastuzumab und Pertuzumab bei metastasiertem Gallenblasenkarzinom
- (2016) E. Czink et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
- (2015) J. Bridgewater et al. ANNALS OF ONCOLOGY
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
- (2015) Alexander Stein et al. BMC CANCER
- Molecular Pathways: IDH2 Mutations--Co-opting Cellular Metabolism for Malignant Transformation
- (2015) E. M. Stein CLINICAL CANCER RESEARCH
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2/neu-directed therapy for biliary tract cancer
- (2015) Milind Javle et al. Journal of Hematology & Oncology
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
- (2015) Juan W Valle et al. LANCET ONCOLOGY
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
- (2014) S. Pant et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials
- (2014) Florian Eckel et al. CHEMOTHERAPY
- Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
- (2014) Alexandra R. Grassian et al. CURRENT OPINION IN GASTROENTEROLOGY
- STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression
- (2014) Hasaya Dokduang et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
- (2014) John Bridgewater et al. JOURNAL OF HEPATOLOGY
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
- (2014) J. S. Ross et al. ONCOLOGIST
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- (2014) Li Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
- (2013) J. W. Valle et al. ANNALS OF ONCOLOGY
- BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
- (2013) Benjamin Goeppert et al. MODERN PATHOLOGY
- Transforming Growth Factor β Neutralization Ameliorates Pre-Existing Hepatic Fibrosis and Reduces Cholangiocarcinoma in Thioacetamide-Treated Rats
- (2013) Hong Ling et al. PLoS One
- Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target
- (2013) A. Saborowski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
- (2013) Steven Steven Sorscher Cancer Management and Research
- Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
- (2012) Giorgio Trinchieri Annual Review of Immunology
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
- (2012) Anne M. Horgan et al. JOURNAL OF CLINICAL ONCOLOGY
- Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma
- (2012) William C. Palmer et al. JOURNAL OF HEPATOLOGY
- HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
- (2012) Joshua Peck et al. ONCOLOGY
- Immunohistochemical evidence of the prognostic value of hedgehog pathway components in primary gallbladder carcinoma
- (2012) Jinmao Li et al. SURGERY TODAY
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
- (2011) Ting-Lei Gu et al. PLoS One
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrahepatic Cholangiocarcinoma
- (2009) Itaru Endo et al. ANNALS OF SURGERY
- Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
- (2009) Takashi Sasaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Notch signaling controls liver development by regulating biliary differentiation
- (2009) Y. Zong et al. DEVELOPMENT
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started